ArticlePloS one2016
Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Pooled it
- Distinct molecular profiles in human aortic smooth muscle cells under cyclic stretch and hydrostatic pressure.The journal of physiological sciences : JPS · 2026Article
- Cellular, Molecular and Clinical Aspects of Aortic Aneurysm-Vascular Physiology and Pathophysiology.Cells · 2024Review
- Microarray Analysis for Transcriptomic Profiling of Myocardium in Patients with Fatal Myocardial Infarction.Biomedicines · 2023Article
- Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin-Deficient Mice via Upregulation of Angiotensin (1-7).Journal of the American Heart Association · 2023Article
- Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin-Deficient Mice.Journal of the American Heart Association · 2022Article
- TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review.Journal of clinical medicine · 2021Review
- Osteoprotegerin Prevents Intracranial Aneurysm Progression by Promoting Collagen Biosynthesis and Vascular Smooth Muscle Cell Proliferation.Journal of the American Heart Association · 2020Article
- Identification of key genes and pathways in abdominal aortic aneurysm by integrated bioinformatics analysis.The Journal of international medical research · 2020Article
- Article
- TRAIL signals, extracellular matrix and vessel remodelling.Vascular biology (Bristol, England) · 2020Review
- The role of osteoprotegerin in the development, progression and management of abdominal aortic aneurysms.Open medicine (Warsaw, Poland) · 2020Review
- Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates.Circulation. Genomic and precision medicine · 2019Article
- Article
- Effects of osteoprotegerin/TNFRSF11B in two models of abdominal aortic aneurysms.Molecular medicine reports · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal aortic aneurysms (AAAs), which commonly occur among elderly individuals, are accompanied by a risk of rupture and subsequent high mortality. Establishment of medical therapies for the prevention of AAAs requires further understanding of the molecular pathogenesis of this condition. This report details the possible involvement of Osteoprotegerin (OPG) in the prevention of AAAs through inhibition of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In CaCl2-induced AAA models, both internal and external diameters were significantly increased with destruction of elastic fibers in the media in Opg knockout (KO) mice, as compared to wild-type mice. Moreover, up-regulation of TRAIL expression was observed in the media by immunohistochemical analyses. Using a culture system, both the TRAIL-induced expression of matrix metalloproteinase-9 in smooth muscle cells (SMCs) and the chemoattractive effect of TRAIL on SMCs were inhibited by OPG. These data suggest that Opg may play a preventive role in the development of AAA through its antagonistic effect on Trail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.